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Background: Lung cancer most often presents as an inoperable tumour and the diagnosis is usually performed on
a small biopsy/cytology specimen. In the group of non small cell lung cancer - not otherwise specified,
adenocarcinoma phenotype can be determined immunohistochemically using TTF-1 and Napsin A. Expression of
oncofetal protein IMP3 in human cancer is associated with poor differentiation and aggressive behaviour. In the
present study expression of IMP3 was correlated with expression of TTF-1 and Napsin A, histological subtype and
clinical stage of lung adenocarcinoma. We were interested whether distant metastases are associated with IMP3
overexpression, regardless of the histologic subtype of adenocarcinoma.
Methods: In retrospective study, consecutive series of 105 patients with advanced lung adenocarcinoma diagnosed
from 2006 to 2009 in Clinical Hospital Center Split, Croatia, were analysed. Clinical data were collected from the
Pulmology Department and time of death from the Mortality Registry. Paraffin blocks of bronchoscopic biopsies
were collected from the Institute of Pathology and 15 cases excluded from the analysis due to insufficient material.
Expression of IMP3, Napsin A and TTF-1 were analysed by indirect enzyme immunohistochemistry. Statistical
analysis was performed and P values less than 0.05 considered significant.
Results: Of 90 patients, 71 (78%) were males and 19 (22%) females. Median age for males was 61.5 years (min-max
43–83) and for females 61 years (min-max 44–86). Pleural effusion was found in 15 (16.6%) and distant metastases
in 45 (50%) cases. According to histological subtypes, there were 34 acinar, 2 lepidic, 2 papillary and 52 solid
subtypes. IMP3 overexpression was found in 63 cases (70%) and was correlated with solid subtype (P = 0.002) and
negative/weak Napsin A expression (P = 0.004). Strong Napsin A expression correlated with TTF-1 expression
(P = 0.003) and lower histological grades (P = 0.031). Patients with IMP3 overexpression more often had distant
metastases than patients with negative IMP3, 55.5% versus 33.3% (P = 0.033). Non solid subtypes with IMP3
overexpression developed distant metastasis more common than non solid subtypes with negative IMP3,
72% versus 35% (P = 0.028).
Conclusions: Expression of IMP3 correlates with solid subtype and with distant metastases regardless of
histological subtype of lung adenocarcinoma.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/1966211581795258* Correspondence: merigdst@yahoo.co.uk
1Institute for pathology, forensic medicine and cytology Clinical Hospital
Center Split, Split, Croatia
Full list of author information is available at the end of the article
© 2012 Beljan Perak et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Beljan Perak et al. Diagnostic Pathology 2012, 7:165 Page 2 of 7
http://www.diagnosticpathology.org/content/7/1/165Zusammenfassung
Hintergrund: Das Lungenkarzinom kommt meistens als nicht resektabler Tumor vor und die Diagnose kann nur in
kleinen Biopsaten oder zytologisch gestellt werden. In der Gruppe der nicht kleinzelligen Lungenkarzinome kann
der nicht anders spezifizierte Adenokarzinom Phänotyp mit Hilfe der Antikörper TTF-1 und Napsin A diagnostiziert
werden. Die Expression des onkoföetalen Proteins IMP3 ist bei humanen Karzinomen mit agressivem Verhalten und
metastatischem Potential verbunden. In dieser Studie korreliert die Expression von IMP3 mit TTF-1, Napsin A,
histologischem Typ und klinischem Staging des Lungenkarzinoms. Wir waren daran interessiert, ob Fernmetastasen
mit IMP3 Überexpression assoziiert sind, unabhängig von der histologischen Subtyp von Adenokarzinom.
Methode: In der retrospektiven Studie wurden die von 2006 bis 2009 im Klinischem Krankenhaus Split, Kroatien
diagnostizerte Adenokarzinome der Lunge von 105 Patienten analysiert. Die klinischen Daten stammten aus der
Abteilung für Pulmologie und im Falle des Todes vom Todesregister. Die Paraffinblöcke der primären
Lungenbiopsate dieser Patienten wurden im Institut für Pathologie mit der indirekter Enzym - Immunohistochemie
mittels Kombination der Antikörper gegen IMP3, Napsin A und TTF1 untersucht. 15 Fälle aus der Analyse aufgrund
unzureichender Material ausgeschlossen. Es wurde eine statistische Untersuchung durchgeführt und Werte weniger
als 0.05 P wurden als statistisch signifikant bezeichnet.
Ergebnisse: Von 90 Patienten mit Lungencarcinom waren 71 (78%) mänlich, durchschnittliches Alter war für
Männer 61.5 Jahre (min-max 43–83) und 61 Jahre für Frauen (min-max 44–86). Pleurale Effusionen fand man in 15
Fällen (16.6%) und Fernmetastasen in 45 (50%) Fällen. Histologische Sybtypen waren: 2 lepidic Karzinome, 34
azinäre Karzinome, 2 papilläre und 52 solide Karzinome. IMP3 war exprimiert in 63 Fälle (70%). Positive IMP3
Expression war mit solidem Typ (P = 0.002) und negativer Napsin A Expression (P = 0.004) assoziert. Napsin A
Expression war mit niedrigem Gradus (P = 0.031) und positiver TTF-1 Expression (P = 0.003) assoziert. Patienten mit
IMP3 Überexpression öfter hatten Fernmetastasen als Patienten mit negativen IMP3, 55.5% versus 33.3% (P = 0.033).
Non solide Subtyp mit IMP3 Überexpression entwickelten Fernmetastasen Meer häufiger als nicht festem Subtyp
mit negativen IMP3, 72% versus 35% (P = 0.028).
Schlussworte: Die Expression von IMP3 ist mit negaativer Expression von Napsin A, solidem Subtyp und
Metastasen verbunden und hat praktische predictive Werte in der pathologischen Diagnose des Adenokarzinoms
der Lunge. Die Expression von IMP3 korreliert mit soliden Subtyp und mit Fernmetastasen unabhängig von
histologische Subtyp Lungenadenokarzinom.
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Lung cancer is the leading cause of cancer mortality in
the world, with the highest incidence in the Western
World and poor overall survival [1]. It presents a com-
plex disease with different phenotypes, variabile
responses to therapy and probably different relationships
to specific carcinogens [2]. Small cell lung carcinomas
(SCLC) and non-small cell lung carcinomas (NSCLC)
are wide and clinically relevant groups of lung cancer.
The most common histologic type of NSCLC is adeno-
carcinoma (ADC), accounting for nearly half of all lung
cancers [3]. There is general agreement that squamous
cell carcinoma (SCC) and SCLC have the highest accur-
acy of diagnosis in small preoperative specimens,
whereas ADC is less accurately diagnosed due to its
histological complexity [4]. Due to advanced clinical
stage at presentation, up to 90% of diagnoses are estab-
lished on small biopsy or cytology specimen [5], but be-
cause of the paucity of bronchoscopic material, careful
selection of ancillary methods (like histochemical mucin
stain, immunohistochemistry and polymerase chainreaction) should be done [6]. Multiplex panel dual
immunohistochemistry using p63/CK 5 and TTF-1/Nap-
sin A are useful in subcategorising NSCLC-NOS into
SCC and ADC phenotypes [7]. Combination of TTF-1
and Napsin A highly improved sensitivity and specificity
for diagnosing lung adenocarcinoma [8]. TTF-1 is a
nuclear tissue-specific DNA-binding protein mainly
expressed in thyroid follicular cells, type II pneumocytes
and nonciliated bronchiolar epithelial cells. Its function
in lungs is transcriptional activation of surfactant pro-
teins and secretory proteins of Clara cells [9]. Napsin A
is aspartic proteinase involved in the maturation of the
surfactant B. It is expressed in the cytoplasm of type II
pneumocytes and Clara cells, in proximal tubular renal
epithelium and exocrine pancreas [10,11]. In the last few
years IMP3, member of insulin-like growth factor II
mRNA binding protein family, was investigated in differ-
ent malignant neoplasms because its overexpression is
generally associated with aggressive and advanced
tumours [12]. Normally, IMP3 is expressed in develop-
ing tissues during embryogenesis and plays the role in
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tion [13]. In adult tissues IMP3 expression is low or un-
detectable, but in malignant tumors is strongly
expressed [14,15]. In most studies increased expression
of IMP3 correlates with aggressive biological behaviour
of the tumour [16,17]. Expression of IMP3 in series of
lung cancer was analysed in few studies. According to
these articles, IMP3 overexpression in high grade neu-
roendocrine carcinoma [18], non small cell lung carcin-
oma [19] and adenocarcinoma [20] correlated with poor
differentiation and advanced stage of disease. In this
study we analysed expression of IMP3 in histological
subtypes of lung adenocarcinoma and its impact on clin-
ical staging.
Methods
From January 2006 till December 2009, 807 new cases of
lung cancer were diagnosed at the Institute of pathology,
forensic medicine and cytology, Clinical Hospital Center
Split, Croatia. The consecutive series of 105 patients
with primary inoperable adenocarcinoma were investi-
gated. Clinical data (age, sex, tumor size, clinical staging)
were collected from the hospital records and time of
death from the Mortality Registry. Overall survival was
evaluated for outcome analysis. Paraffin blocks were col-
lected from the Institute of pathology, forensic medicine
and cytology and 15 cases were excluded due to insuffi-
cient material. Indirect immunohistochemical analysis
was performed on 5-μm sections using primaryFigure 1 Expression of TTF-1, Napsin A and IMP3 in lung adenocarcin
malignant cells are positive to TTF-1, C Weak cytoplasmatic granular positiv
E Negative expression od IMP3, F positive expression of IMP3 (200x).monoclonal mouse antibodies against IMP3 (dilution
1:200), Napsin A (dilution 1:200) and TTF-1 (dilution
1:100), EnVision/HRP and chromogen 3,3'-diaminobenzi-
dine (all reagents DAKO, Glostrup, Denmark). The slides
were analysed with light microscope Olympus 51BX by
two pathologists. Diffuse cytoplasmic staining for IMP3,
nuclear staining for TTF-1 and granular cytoplasmic stain-
ing for Napsin A were considered positive. Expression of
TTF-1 and IMP3 was assessed as positive or negative
and expression of Napsin A as negative/weak or
strongly positive (Figure 1). Cases with more than 10%
of positive cells were considered as positive. Statistical
analysis was performed using the SPSS 19 system for
Windows and P value less than 0.05 was considered sta-
tistically significant.
Results
In the sample were 90 patients, 71 (78%) males and 19
(22%) females. Median age for males was 61.5 years (min-
max 43–83) and for females 61 years (min-max 44–86). In
five years of follow up, 79 (87%) patients died. The mean
overall survival was 8 months (95% CI 1–34 months). Me-
dian survival was 2,5 times longer in patients without
distant metastases: 9 months (SE 1.8 months) (95% CI
5.4-12.6) compared to patients with metastases: 4 months
(SE 1.1) (95% CI 1.9-6.1) (log rank 6.5 P = 0.011). The
pleural effusion was present in 15 (16.6%) cases and in 14
patients was cytologically malignant. In the beginning of
diagnostic procedure 19 patients were examined withoma. A Tumor tissue infiltrates bronchal mucosa, B Nuclei of
ity to Napsin A. D Strong granular cytoplasmatic positivity to Napsin A.
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abdomen and staged into T2 (5), T3 (7) and T4 (7) cat-
egories; the remaining patients only had chest radiog-
raphy. Median tumour size was 58.5 mm (min-max 21–
112). Radiographic evidence of significantly enlarged and
presumably positive regional lymph nodes had 51 (56.6%)
patients. In the analysed period 45 (50%) patients devel-
oped distant metastases in bones (14), brain (10), liver (5),
adrenal glands (4), or multiple sites (12). Histological grad-
ing was performed according to the presence of solid
component and cytological atypia [21], resulting in 18 well
differentiated, 23 moderately differentiated and 49 poorly
differentiated tumours. According to the criteria set forth
by the WHO (2004), there were 34 acinar, 2 lepidic, 2 pap-
illary and 52 solid subtypes; in further analysis solid sub-
type has been compared to others.
According to Table 1, positive expression of IMP3 was
found in 61 (67.7%) cases. Median age of patients with
positive IMP3 expression was 58.5 years (min-max 43–
83) and of patients with negative IMP3 expression
63 years (53–79) (Z = 1,75 P = 0.08). Median tumor size
was 58.5 mm (min-max 21–112) in IMP3 positive
patients and 60 mm (min-max 22–108) in IMP3 negative
patients (Z = 0.82 P = 0.411). No statistically significant











Pleural effusion no 29
yes 15
T staging 2 10
3 10
4 20
N staging 1 20
2 14
3 1
M staging 0 31
1a 14
1b 45
χ2 test.pleural effusion (χ2 = 3.5 P = 0.063), histological grade (χ2 =
2.499 P = 0.287) and TTF-1 expression (χ2 =0.276 P =
0.599). Overexpression of IMP3 correlates to solid sub-
type (χ2 =9.4 P = 0.002) and negative Napsin A expres-
sion (χ2 =8.25 P = 0.004). In the group of 52 cases with
solid subtype, 43 (82.6%) had IMP3 overexpression and
in the group of 38 cases with other subtypes 20 (52.6%).
IMP3 overexpression correlated with presence of distal
metastases (staging M1b) (χ2 = 6.844 P = 0.033).
Table 2 shows the distribution of metastases according
to IMP3 overexpression in patients with non solid sub-
type of adenocarcinoma. Among 18 patients with distant
metastases, 13 (72%) were IMP3 positive. Among 20
patients without distant metastases, IMP3 was positive
in 7 (35%) cases. In non solid subtypes, IMP3 overex-
pression was more often found in patients who devel-
oped metastasis (Fisher exact test P = 0.028). IMP3
positive cases had shorter time of overall survival, but
result is not statistically significant (log rank 0.14 P =
0.713). Patients with negative IMP3 expression had
mean survival 9 months (SE 2 months) (95% CI 5–
12 months) and patients with positive IMP3 had mean
survival 9 months (SE 1 month) (95% CI 4–6 months).
Expression of Napsin A was not related to sex (χ2 =1.577
P = 0.209) and pleural effusion (χ2 = 0 P = 1). In cases withoma
IMP3 (N = 90) P
Negative N (%) Positive N (%)
8 (29.6) 10 (15) 0.287
7 (25.9) 16 (25)
12 (44) 37 (58)
9 (33) 43 (68) 0.002
18 (66) 20 (31)
12 (46) 48 (77) 0.004
14 (53) 14 (22)
9 (33.3) 22 (39.2) 0.599
18 (66.6) 34 (60.7)
6 (42.8) 3 (76.6) 0.063
8 (16.6) 7 (23.3)
4 (33.3) 6 (21.4) 0.458
2 (16.6) 8 (28.5)
6 (50) 14 (50)
9 (64) 11 (52.3) 0.612
5 (35) 9 (42.8)
0 1 (4)
10 (37) 22 (34.9) 0.033
8 (29.6) 6 (9.5)
9 (33.3) 36 (55.5)
Table 2 IMP3 in non solid subtypes of lung adenocarcinoma and distant metastasis
Non solid subtypes (N = 38) IMP3 Distal metastasis P
negative positive
18 5 (27.7) 13 (72.2) yes 0.028
20 13 (65) 7 (35) no
Fisher exact test.
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59 mm (min-max 23–112) and with positive Napsin A ex-
pression 59.98 mm (min-max 21–108) (Z = 0.518 P =
0.605). Napsin A expression correlated with TTF-1 positiv-
ity (χ2 = 8.986 P = 0.003) and lower histological grade
(χ2 = 8.986 P = 0.003).
Discussion
About 70-80% of lung carcinomas fall under the classifi-
cation of NSCLC with adenocarcinoma as the most
common subtype [22]. In the past, all subtypes of
NSCLC received the same therapy and subclassification
was not important for the treatment or prognosis. Re-
cent development in the treatment strategies necessitates
further cytological and histological subtyping of NSCLC.
Promotor methylation was more common find in squa-
mous carcinoma and correlated to pleural indentation
[23]. Activated gene mutations are more common found
in adenocarcinoma [2]. New biologically targeted che-
motherapies, such as bevacizumab, have clinical benefits
in patients with ADC, but strong contraindications in
SCC cases. There are therapies that target EGFR
mutations and ALK fusion genes which are found almost
exclusively in adenocarcinomas. Architecture of pulmon-
ary adenocarcinoma is very heterogeneous. Morphologic
features, as specified in the WHO classification 2004,
have been the standard for NSCLC subtyping, but
according to Terry et al. [7], 25% of bronchoscopic biop-
sies cannot be subclassified by morphology alone so
immunohistochemical and/or genetic analyses are neces-
sary. Immunohistochemical markers TTF-1 and Napsin
A are nowadays a useful tool in adenocarcinoma identifi-
cation and their dual use improves diagnostic accuracy,
but does not give us data about prognosis of cancer
which often has high metastatic potential. There have
been some studies about prognostic value of some histo-
logical characteristics [9,21] or methylation markers
[23]. We tried to obtain this important prognostic infor-
mation using antibody to oncofetal protein IMP3, previ-
ously identified as a marker of aggressive behaviour in
various tumours.
Expression of IMP3 was analysed in relation with
histological grade proposed by Barletta et al. [21], but no
significant correlation was found (P = 0.287). According
to some authors, [24] there is no well-established histo-
logical or cytological grading scheme for NSCLC andcurrently applied subjective grading is not prognostically
relevant. In our series solid subtype was the most com-
mon and it was analysed in relation to other subtypes
(acinar, lepidic and papillary) grouped together. One case
of papillary subtype had characteristics of recently
described stromal micropapillary pattern [25,26]. IMP3
overexpression correlated with solid subtype (P = 0.002).
In the series of 89 surgically resected specimens Findeis-
Hosey et al. have found that positive IMP3 expression
was strongly correlated with poorly differentiated adeno-
carcinoma and solid component of myxed subtype
adenocarcinoma [20]. In our study, expression of TTF-1
and Napsin A were 61% and 51%, respectively. TTF-1
expression value was within reported range [9], but per-
centage of Napsin A positive cases was surprisingly low
[27]. Possible explanation for this could be high propor-
tion of solid subtype in our series, although technical
problems in sampling and fixation could not be
excluded. Expression of Napsin negatively correlated
with poor differentiation and 40 (76.9%) cases of
histologic grade 3 were Napsin A negative (P = 0.031).
Expression of TTF-1 did not correlate with grade
(P = 0.542), which confirmed objection of Ueno et al. [27]
that TTF-1 showed no association with the grade of
tumour differentiation. Both TTF-1 and Napsin A were
negative in 28 cases, majority of those were of solid sub-
type and immunohistochemically negative to Cytokeratin
5/6. The proportion of dual negative cases in our study
was higher than in study of Turner et al. [8], 32% versus
10.6%, respectively which could be explained by high per-
centage of solid subtype in our sample. IMP3 overexpres-
sion correlated with negative expression of Napsin A (P =
0.004), but correlation of IMP3 and TTF-1 was not found
(P = 0.599).
During five-year follow-up, out of 90 patients with
inoperable lung adenocarcinoma, 79 (8.77%) died.
The mean overall survival was 8 months (95% CI
1–34 months). IMP3 overexpression had no influence on
mean overall survival (P = 0.712). We did not find statis-
tically significant difference in tumour size (P = 0.411),
T staging (P = 0.458) or N staging (P = 0.612) among
IMP3 overexpressed and IMP3 negative cases. Findeis-
Hosey et al. found that IMP3 is more frequently
expressed in larger tumours with positive lymph nodes
or higher clinical stage, but the difference was not statis-
tically significant [20].
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to the brain, liver, adrenal glands, bones or to multiple
sites. Quite often symptoms of metastases were the first
sign of the malignancy. IMP3 overexpression showed
correlation with distant metastases regardless of histo-
logical subtype (P = 0.033). Further series are needed to
confirm these results and eventually establish IMP3 in
initial immunohistochemical panel for small broncho-
scopic biopsy/cytology, as a marker for aggressive behav-
iour and higher metastatic potential of lung
adenocarcinoma.
In conclusion, IMP3 overexpression correlated with
solid subtype and negative expression of Napsin A, as
well as distant metastasis regardless of hystological sub-
type. Our results confirm that positive IMP 3 expression
predicts aggressive tumour behaviour in lung adenocar-
cinoma and can be used as a significant predictor of un-
favorable outcome.
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